And * • Parkinson's Institute and Clinical Center, Sunnyvale, CA, United States Alpha-synuclein ( non A4 component of amyloid precursor, SNCA, NM_000345.3) plays a central role in the pathogenesis of Parkinson's disease (PD) and related Lewy body disorders such as Parkinson's disease dementia, Lewy body dementia, and multiple system atrophy. Since its discovery as a disease-causing gene in 1997, alpha-synuclein has been a central point of scientific interest both at the protein and gene level. Mutations, including copy number variants, missense mutations, short structural variants, and single nucleotide polymorphisms, can be causative for PD and affect conformational changes of the protein, can contribute to changes in expression of alpha-synuclein and its isoforms, and can influence regulation of temporal as well as spatial levels of alpha-synuclein in different tissues and cell types. A lot of progress has been made to understand both the physiological transcriptional and epigenetic regulation of the alpha-synuclein gene and whether changes in transcriptional regulation could lead to disease and neurodegeneration in PD and related alpha-synucleinopathies. Although the histopathological changes in these neurodegenerative disorders are similar, the temporal and spatial presentation and progression distinguishes them which could be in part due to changes or disruption of transcriptional regulation of alpha-synuclein. In this review, we describe different genetic alterations that contribute to PD and neurodegenerative conditions and review aspects of transcriptional regulation of the alpha-synuclein gene in the context of the development of PD. New technologies, advanced gene engineering and stem cell modeling, are on the horizon to shed further light on a better understanding of gene regulatory processes and exploit them for therapeutic developments.

We DO NOT store any content of the torrent,Our DHT-ROBOT functionally gather and store the metadata such as the name,size, infohash or file-list of a torrent from the DHT network. Please pay attention that we are not responsible for the authenticity and legality of the torrent. G, Patelarou E, Petersen MS, Torrent M, Trnovec T, Valvi. Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J. DeRoos P, Liu. Uses the coordinate descent algorithm.16 Models were tuned via 20-fold cross-validation, us.

Download shivji bhajans of gulshan kumar. Introduction Alpha-synuclein ( non A4 component of amyloid precursor, SNCA, chr4q21-22, NM_000345.3, MIM #163890) was the first gene in which a causative mutation for Parkinson's disease (PD) was discovered in 1997 (; ). The detection of alpha-synuclein protein as a constituent of Lewy bodies further strengthened the role of alpha-synuclein in PD and dementia with Lewy bodies (DLB) as a central player in the pathogenesis of neurodegeneration (; ). It is now well-established that rare point mutations and large genomic multiplications of the SNCA gene can cause autosomal-dominant parkinsonism which can present itself as a wide range of clinical and histopathological features including typical PD (), Parkinson's disease dementia (PDD), DLB (), multiple system atrophy (MSA) (), or even fronto-temporal dementia (FTD) (;;;;;;;;; ). Genetic variants in the non-coding region of the SNCA gene, including single nucleotide polymorphisms (SNPs) were discovered by association and genome wide association studies (GWAS) (; ) and small structural variants increase the risk for developing PD (), however the underlying mechanisms are still under investigation as will be reviewed herein. The mere overexpression of wildtype alpha-synuclein in patients with SNCA multiplications is sufficient to cause parkinsonism and point mutations in the SNCA gene seem to increase alpha-synuclein inclusion formation or its interaction with acidic phospholipids suggesting that alpha-synuclein, when mutated, causes neurodegeneration and parkinsonism via a toxic gain-of-function mechanism (; ). Interest in alpha-synuclein as a therapeutic target for PD has been growing not only due to the genetic link, but also because of the pathology of alpha-synuclein spreading through the nervous system and the cell-to-cell propagation of aggregated alpha-synuclein. These observations have led to consensus that lowering the alpha-synuclein content and/or eliminating toxic alpha-synuclein species in cells could be the key to slowing, reversing, or even preventing the disease and such alpha-synuclein lowering therapeutic strategies are currently being developed (; ).